After Yemen-based Houthi rebels have targeted ships in the Red Sea...
Category:
Non-Life
Latest
Life protection plan for Indian blue-collar workers unveiled in the UAE
Around 3.5 million Indians reside in the UAE, of which about 65 per...
Number of farmers under PM’s crop insurance scheme rises by 27 pc in 2023-24: Govt
During this period, a total amount of nearly Rs 31,139 crore was...
How India’s premier cyber agency is fighting evolving threats
According to Dr Sanjay Bahl, Director-General, CERT-In, they have seen different set of attacks during the pandemic and the threat actors primarily employed references related to COVID-19 in phishing attacks to steal sensitive information and drop additional malware.
“The threat actors devised new strategies to target victims with scams or malware campaigns using legitimate corporate branding in the name of COVID-19 and names of trusted organisations in phishing attacks in order to attain credibility and to lure victims,” Bahl told IANS.
Kia Motors recalling 295,000 vehicles due to risk of engine fires
Last week, the National Highway Traffic Safety Administration announced that Kia and Hyundai must pay USD 137 million in fines and for safety improvements because they moved too slowly to recall more than 1 million vehicles with engines that can fail.
The fines resolve a three-year government probe into the companies’ behavior involving recalls of multiple models dating to the 2011 model year.
Vaccine airlift delivers shot in the arm for airlines
IATA, representing 290 airlines, warns that vaccine rollout could be “compromised” without an easing of the travel curbs and quarantines it has lobbied against.
“There are parts of the world that have no cargo operations once the passenger networks are grounded,” IATA head of cargo Glyn Hughes said.
India considering accelerated review of COVID-19 vaccine emergency use
“We are in the process of reviewing. It is an accelerated reviewing process, which is there for Serum too,” the government official said. “All applications are accelerated. It is the need of the hour.”
Cyber insurance shifting into personal lines as consumer interest rises in UK:GlobalData
Daniel Pearce, Senior Insurance Analyst at GlobalData, comments: “The need for cyber insurance policies has long been identified in the commercial space, where reliance on technology for day-to-day business activities has grown at an exponential rate. However, individuals have also become increasingly dependent on technology. With their exposure to cyber risks growing, the personal cyber insurance market is burgeoning.”
Country will not have to wait too long for COVID-19 Vaccine:PM Modi
“However, there should be no laxity from our side as far as prevention of the infection is concerned. Masks and a distance of two yards is very necessary,” Modi said.
ICICI Lombard and PLUM to provide technologically powered group health insurance products
Abhishek Poddar, Co-founder & CEO of Plum added, “The group insurance health market in India is projected to grow to Rs 100,000 crores by 2025, and will see the rise of innovative insurance products not available in advanced markets. ”
Covid 19 Pandemic to hit life insurers’ investment income,ULIP and Pension and Annuity business:LIC Chief
TR Alamelu, member, IRDAI explained that that the solution to the issue of under-insurance in the country does not lie in mandating insurance because a stage has been reached where insurance should be a product on “demand” and It cannot be forced upon consumers by the industry or other stakeholders.
Tokyo Olympics delay costs near $2.8 billion
About two-thirds of the added costs are being picked up by the two government entities, with the other one-third going to the privately funded organizing committee.
Serum likely to supply COVID-19 vaccine at over $3 a dose to Indian government
The government is pinning its hopes for mass supply on Serum Institute, which lodged the first formal application for emergency-use approval of AstraZeneca’s shot on Monday.
Chief Executive Officer Adar Poonawalla had earlier said the vaccine would be priced at 1,000 rupees ($13.55) per dose in India’s private market, but governments signing large supply deals would likely buy it at lower prices.